Ursula A. Matulonis

Broad Institute

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

5.6Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

Nature Medicine(2020)10.1038/s41591-020-0844-1

Top 4%

5.6DataRank

Top 4%819 citations

Caroline B. M. Porter, Orr Ashenberg, Julia Waldman, Eugene Drokhlyansky, Isaac Wakiro +45 more

Papers

Driven by 32 papers — median percentile 0. Top paper: “A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors”.

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

Nature Medicine(2020)10.1038/s41591-020-0844-1

Top 4%

5.6DataRank

Top 4%819 citations

Caroline B. M. Porter, Orr Ashenberg, Julia Waldman, Eugene Drokhlyansky, Isaac Wakiro +45 more

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30180-7

N/A

5.1DataRank · unranked

233 citations

Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle +19 more

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Journal of Clinical Oncology(2022)10.1200/jco.21.02011

N/A

2.6DataRank · unranked

88 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +16 more

A single-cell and single-nucleus RNA-seq toolbox for fresh and frozen human tumors

bioRxiv (Cold Spring Harbor Laboratory)(2019)10.1101/761429

N/A

2.5DataRank · unranked

68 citations

Orr Ashenberg, Julia Waldman, Eugene Drokhlyansky, Isaac Wakiro, Indresh Singh +44 more

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3045

N/A

1.5DataRank · unranked

64 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

A single-cell landscape of high-grade serous ovarian cancer

Nature Medicine(2020)10.1038/s41591-020-0926-0

N/A

0.938DataRank · unranked

518 citations

Itay Tirosh, Elizabeth H. Stover, Isaac Wakiro, Michael S. Cuoco, Idan Alter +30 more

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers

BMC Cancer(2020)10.1186/s12885-020-6605-1

N/A

0.646DataRank · unranked

34 citations

Thomas A. Davis, Abdelrahman Hosny, Julia Eismann, Ursula A. Matulonis, Gerburg M. Wulf +2 more

Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma

Cancer Research Communications(2025)10.1158/2767-9764.crc-24-0028

N/A

0.112DataRank · unranked

1 citations

Saie Mogre, Hyeji Jun, Ruiyang He, Sneha Ghosh Chaudhary, Upendra Raj Bhattarai +8 more

Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions

Cancers(2021)10.3390/cancers13092195

N/A

0DataRank · unranked

2 citations

Joyce F. Liu, Nikolas Kesten, Kin-Hoe Chow, Aniket Shetty, Ruiyang He +13 more

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

Nature Communications(2022)10.1038/s41467-022-30568-1

N/A

0DataRank · unranked

255 citations

Johann S. Bergholz, Liya Ding, Ziying Lin, Sheheryar Kabraji, Melissa E. Hughes +14 more

Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2834

N/A

0DataRank · unranked

35 citations

Nabihah Tayob, Livius Penter, MacLean Sellars, Anna Tarren, Vipheaviny Chea +19 more

Satellite repeat RNA expression in epithelial ovarian cancer associates with a tumor-immunosuppressive phenotype

Journal of Clinical Investigation(2022)10.1172/jci155931

N/A

0DataRank · unranked

24 citations

Siyu Sun, Micayla N. Flores, Emily Berzolla, Eunae You, Ildiko E. Phillips +22 more

Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer

British Journal of Cancer(2022)10.1038/s41416-022-01901-8

N/A

0DataRank · unranked

20 citations

Tianyi Wang, Mary K. Townsend, A. Heather Eliassen, Fred K. Tabung, Edward L. Giovannucci +5 more

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.100974

N/A

0DataRank · unranked

15 citations

Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak +14 more

910 STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0910

N/A

0DataRank · unranked

5 citations

Qiwei Wang, Antons Martincuks, Michael Kearns, Tao Jiang, Ziying Lin +12 more

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005627

N/A

0DataRank · unranked

93 citations

Qiwei Wang, Antons Martincuks, Michael J. Kearns, Tao Jiang, Ziying Lin +13 more

Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0313

N/A

0DataRank · unranked

85 citations

Connie Wu, Peter C. Fridy, Stephanie J. Zhang, Yasmeen Senussi, Justina C. Wolters +54 more

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5512

N/A

0DataRank · unranked

6 citations

Elizabeth Katherine Lee, Su–Chun Cheng, Alexandre André Balieiro Anastácio da Costa, Andrea E. Wahner Hendrickson, D. Gulhan +14 more

Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e13003

N/A

0DataRank · unranked

1 citations

Shizong Ke, Ruolin Liu, Tim Blewett, Justin Rhoades, D. Gulhan +5 more

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290.v1

Top 100%

0DataRank

Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290

Top 100%

0DataRank

Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Data from Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

(2023)10.1158/1078-0432.c.6532794

N/A

0DataRank · unranked

0 citations

D. Gulhan, Victor Y. Mao, Antuan V. Tran, Madeline Polak, Niya Xiong +14 more

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135

N/A

0DataRank · unranked

36 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

Ovarian Sex Cord Tumor With Annular Tubules (SCTAT) Harbor Recurrent Copy Number Alterations, Including Monosomy 22

Modern Pathology(2025)10.1016/j.modpat.2025.100891

N/A

0DataRank · unranked

1 citations

Alexander Neil, Stephanie Siegmund, Amir Dehghani, Azra H. Ligon, Ursula A. Matulonis +5 more

Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-X L degradation to overcome cancer chemoresistance

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.06.24.661170

N/A

0DataRank · unranked

11 citations

Adam Presser, Lissah Johnson, Yusuke Matoba, Brendan Shay, Weiyi Xu +19 more

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.02.008

N/A

0DataRank · unranked

157 citations

Ofir Cohen, Bose Kochupurakkal, D. Kim, Connor E. Dunn, Jorge Buendia +20 more

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer

Cancer Research(2020)10.1158/0008-5472.can-20-1674

N/A

0DataRank · unranked

217 citations

Matthew P. Keany, Han Dong, Linah Al-Alem, Unnati M. Pandya, Suzan Lazo +22 more

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100546

N/A

0DataRank · unranked

18 citations

Zhenying Tan‐Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch +6 more

A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.6003

N/A

0DataRank · unranked

56 citations

Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher +15 more

Patient-reported and clinician-rated performance status and general health among women with gynecologic cancers on palliative chemotherapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e24128

N/A

0DataRank · unranked

0 citations

Embree Thompson, Gang Lü, Nancy L. Keating, Ursula A. Matulonis, Susana M. Campos +6 more

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Nature Communications(2021)10.1038/s41467-021-25904-w

N/A

0DataRank · unranked

69 citations

Alexandre André Balieiro Anastácio da Costa, D. Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson +14 more

Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.03.011

N/A

0DataRank · unranked

46 citations

Alexander Melamed, Allison Gockley, Jessica L. Floyd, Kate J. Krause, Robert L. Coleman +5 more

Ursula A. Matulonis

Indexed papers

Top data-sharing exemplar

Papers